The clinically relevant GSI PF-03084014, combined with fludarabine, has antitumor effects in primary NOTCH1-mutated CLL cells30 and, when tested in phase I clinical trials, showed good tolerance and antitumor activity in solid and hematological malignancies31,32. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.